Efficacy of two Dosing Frequencies of Subcutaneous Interferon Beta-1a on the Risk of Conversion from a First Demyelinating Event to Multiple Sclerosis and on MRI Measures of Disease: 3-Year Results of Phase III, Double-Blind, multicentre trials (REFLEX and REFLEXION)